Aperture Investors’s Takeda Pharmaceutical TAK Stock Holding History

Aperture Investors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-36,600	Closed	-$514K	–	96
2022 Q2	$514K	Buy	+36,600	New	+$522K	0.09%	74

Other funds holding TAK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Aperture Investors's TAK Position: Q3 2022 in Review

Aperture Investors sold out of Takeda Pharmaceutical (TAK) in Q3 2022, closing a stake of 36,600 shares — an estimated $514K sold.

Aperture Investors first reported a position in TAK in Q2 2022 and held it in 1 quarter. The position peaked at $514K in Q2 2022. 276 funds tracked by Wall St. Rank hold TAK as of Q3 2022.

Aperture Investors reported no remaining Takeda Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Aperture Investors sold 36,600 Takeda Pharmaceutical shares in Q3 2022, an estimated $514K.
Aperture Investors first reported a position in Takeda Pharmaceutical in Q2 2022 and held it in 1 quarter.
Aperture Investors's Takeda Pharmaceutical position peaked at $514K in Q2 2022.
276 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2022.

Based on Aperture Investors's 13F filing for Q3 2022, filed 14 Nov 2022.